Compare Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Tax Managed Fund FTSE Developed Markets ETF vs 22nd Century Group Inc — how do they compare? Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.34 (market cap $323.80B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 520855.1× 22nd Century Group Inc's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days and 22nd Century Group Inc for 32 Days on average.
| VEA | XXII | |
|---|---|---|
Market Cap | $323.80B | $621.67K |
Volume | 17,001,112 | 45,625 |
52-Week High | $73.79 | $483.00 |
52-Week Low | $58.90 | $0.80 |
Typical Hold Time | 131 Days | 32 Days |
Sector | — | Consumer Staples |
Enterprise Value | — | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VEA trades at $70.21, down 0.07% with bearish technical signals dominating. The ETF shows mixed institutional activity with several firms increasing positions while others reduced exposure. Recent news highlights VEA's competitive advantages including its 0.03% expense ratio and focus on developed markets excluding the U.S. The current technical setup shows oversold conditions with RSI at 28.40 suggesting potential near-term bounce opportunity.
VEA presents a cost-efficient developed markets exposure with strong dividend yield appeal, though technical indicators signal caution. Key risks include global market volatility and currency fluctuations. The ETF's institutional ownership trends and competitive expense ratio support its long-term positioning for investors seeking international diversification beyond U.S. markets.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
